Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes

J Neurochem. 2007 Jul;102(1):179-93. doi: 10.1111/j.1471-4159.2007.04562.x. Epub 2007 Apr 16.

Abstract

KCNQ2 and KCNQ3 subunits encode for the muscarinic-regulated current (I(KM)), a sub-threshold voltage-dependent K+ current regulating neuronal excitability. In this study, we have investigated the involvement of I(KM) in dopamine (DA) release from rat striatal synaptosomes evoked by elevated extracellular K+ concentrations ([K+]e) and by muscarinic receptor activation. [3H]dopamine ([3H]DA) release triggered by 9 mmol/L [K+]e was inhibited by the I(KM) activator retigabine (0.01-30 micromol/L; Emax = 54.80 +/- 3.85%; IC50 = 0.50 +/- 0.36 micromol/L). The I(KM) blockers tetraethylammonium (0.1-3 mmol/L) and XE-991 (0.1-30 micromol/L) enhanced K+-evoked [3H]DA release and prevented retigabine-induced inhibition of depolarization-evoked [3H]DA release. Retigabine-induced inhibition of K+-evoked [3H]DA release was also abolished by synaptosomal entrapment of blocking anti-KCNQ2 polyclonal antibodies, an effect prevented by antibody pre-absorption with the KCNQ2 immunizing peptide. Furthermore, the cholinergic agonist oxotremorine (OXO) (1-300 micromol/L) potentiated 9 mmol/L [K+]e-evoked [3H]DA release (Emax = 155 +/- 9.50%; EC50 = 25 +/- 1.80 micromol/L). OXO (100 micromol/L)-induced [3H]DA release enhancement was competitively inhibited by pirenzepine (1-10 nmol/L) and abolished by the M3-preferring antagonist 4-diphenylacetoxy N-methylpiperidine methiodide (1 micromol/L), but was unaffected by the M1-selective antagonist MT-7 (10-100 nmol/L) or by Pertussis toxin (1.5-3 microg/mL), which uncouples M2- and M4-mediated responses. Finally, OXO-induced potentiation of depolarization-induced [3H]DA release was not additive to that produced by XE-991 (10 micromol/L), was unaffected by retigabine (10 micromol/L), and was abolished by synaptosomal entrapment of anti-KCNQ2 antibodies. Collectively, these findings indicate that, in rat striatal nerve endings, I(KM) channels containing KCNQ2 subunits regulate depolarization-induced DA release and that I(KM) suppression is involved in the reinforcement of depolarization-induced DA release triggered by the activation of pre-synaptic muscarinic heteroreceptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blotting, Western
  • CHO Cells
  • Carbamates / pharmacology
  • Cricetinae
  • Cricetulus
  • Dopamine / metabolism*
  • Electrophysiology
  • Fluorescent Antibody Technique
  • KCNQ2 Potassium Channel / metabolism*
  • KCNQ3 Potassium Channel / metabolism
  • Male
  • Microscopy, Confocal
  • Muscarinic Agonists / pharmacology
  • Muscarinic Antagonists / pharmacology
  • Neostriatum / metabolism*
  • Nerve Endings / drug effects
  • Nerve Endings / metabolism
  • Patch-Clamp Techniques
  • Phenylenediamines / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Muscarinic / metabolism*
  • Receptors, Presynaptic / metabolism*
  • Synaptosomes / metabolism*

Substances

  • Carbamates
  • KCNQ2 Potassium Channel
  • KCNQ3 Potassium Channel
  • Kcnq2 protein, rat
  • Kcnq3 protein, rat
  • Muscarinic Agonists
  • Muscarinic Antagonists
  • Phenylenediamines
  • Receptors, Muscarinic
  • Receptors, Presynaptic
  • ezogabine
  • Dopamine